Bull case
BioCardia is supported by multiple de-risking catalysts: FDA Q-sub minutes for CardiAMP HF and Helix showed no safety concerns and a potential PMA/De Novo path, while PMDA feedback in Japan indicated U.S. trial data may be sufficient for clearance, with a Shonin submission anticipated in 4Q26. The clinical package is also improving, as CardiAMP HF showed durable two-year benefits, including 20.9% fewer heart-death equivalents, 44.6% fewer non-fatal MACCE, and meaningful QoL gains, with the strongest signal in the >500 pg/mg NT-proBNP subgroup, where LV remodeling and a p=0.02 win ratio strengthen the case for the ongoing confirmatory trial. In parallel, CardiAMP CMI and CardiALLO-HF have shown encouraging safety and early efficacy, and the exclusive Heart3D partnership adds a potential commercial revenue stream that could support financing and partnerships.